Kyntra Bio Inc

Kyntra Bio Inc operates with a negative equity position of $228.12 million and a cash and equivalents balance of $68.57 million, indicating a liquidity position that is constrained by its $89.66 million in long-term debt. The company's enterprise value to revenue ratio of 1.95 suggests a premium valuation relative to its current revenue of $25.36 million, but its negative EBITDA of $49.18 million results in an EV/EBITDA of -1.01, signaling significant operational losses.

Profitability metrics reveal a challenging financial landscape. The company's return on equity of 14.44% is misleading due to the negative equity base, while its return on assets of -9.00% reflects the drag from operating losses. Gross profit of $4.02 million is insufficient to cover operating expenses, which are $49.18 million in the red, indicating a lack of operational efficiency and a heavy reliance on external financing.

Geographically and segment-wise, Kyntra Bio Inc does not disclose specific revenue concentrations in its latest financials, but as a pre-revenue biotechnology firm, its exposure is primarily to the U.S. market and clinical-stage drug development. The company's pipeline is its primary asset, with no disclosed revenue-generating products to date.

Growth expectations are mixed. The company is projected to maintain a negative revenue trajectory in the current fiscal year, with no clear path to positive earnings in the near term. Analysts have assigned a mean price target of $43.00, but the absence of strong-buy ratings and the presence of one "buy" and one "hold" recommendation suggest cautious optimism at best.

Risk factors include a high liquidity risk due to negative net cash and a debt-to-equity ratio of -0.39, which is not a traditional measure of leverage but reflects the company's negative equity. The risk of dilution is currently low, but the company's negative free cash flow of $48.64 million and operating cash flow of $59.29 million indicate a continued need for capital infusions, which could lead to future share dilution.

Recent events include the filing of a 10-K for the fiscal year ending December 31, 2023, which disclosed ongoing clinical trials for its lead candidate, KY1005, and a strategic partnership with a major pharmaceutical firm for the development of IL-17 inhibitors. No recent earnings call transcripts were available for analysis.

Kyntra Bio Inc (KYNB.O) has recorded a notable addition to its shareholder base, with a new investor acquiring 181,973 shares valued at approximately $1.60 million as of December 31, 2025. This transaction, detected on June 20, 2026, represents the first analysis for this ticker, meaning there is no prior basis for computing delta changes in ownership or financial metrics. The new holding accounts for a weight of 0.000023% in the investor's portfolio, indicating a relatively small but distinct entry into the company's equity structure. The significance of this move lies in the context of Kyntra Bio's current market profile. The company is currently followed by five analysts, suggesting a baseline level of professional scrutiny despite the absence of index membership. With five top holders identified in the broader dataset, the addition of this new investor contributes to the evolving composition of the shareholder registry, potentially signaling early-stage interest from institutional or sophisticated capital. From a fundamental perspective, Kyntra Bio operates with a reported officer count of zero in the available data, which may reflect specific reporting structures or data availability constraints rather than operational status. The lack of prior material changes or cross-source signals further underscores that this shareholder addition is an isolated event within the current reporting window, devoid of accompanying corporate actions or financial restatements. For investors, this development matters as it marks the initial recorded activity in the company's ownership dynamics. While the share count and value are modest, the entry of a new holder into a company with limited analyst coverage and no index presence can serve as an early indicator of shifting sentiment. Stakeholders should monitor whether this initial position expands or if it triggers further interest from the five analysts currently tracking the stock.

Analysts project 489% upside to a $43 target price, signaling strong institutional confidence in future growth potential.

Net income surged 485.6% year-over-year to $183.5 million in FY2026, marking a significant turnaround from prior losses.

Debt-to-equity ratio of -0.39 is rated best-in-class within the pharmaceutical cohort, suggesting a robust balance sheet structure.

Cash conversion ratio of 1.8 exceeds the cohort median of 0.95, demonstrating superior ability to convert earnings into cash.

High credit risk and negative interest coverage of -5.24 signal significant financial distress and potential solvency concerns for the firm.

Free cash flow remains deeply negative at -$57.5 million in FY2026, indicating continued reliance on external financing to sustain operations.

Revenue $1.3M, −59,3% YoY; Operating income +85,3% YoY.

• ▍Revenue $1.3M, −59,3% YoY
• ▍Operating income +85,3% YoY
• ▍Net income −179,1% YoY
• ▍Free cash flow +82,8% YoY
• ▍Net margin -1113.5%

Revenue $1.1M, +774,8% YoY; Operating income +74,8% YoY.

• ▍Revenue $1.1M, +774,8% YoY
• ▍Operating income +74,8% YoY
• ▍Net income +1 274,4% YoY
• ▍Free cash flow +72,8% YoY
• ▍Net margin 18646.5%

Revenue $1.3M, +35,1% YoY; Operating income +74,0% YoY.

• ▍Revenue $1.3M, +35,1% YoY
• ▍Operating income +74,0% YoY
• ▍Net income +51,1% YoY
• ▍Free cash flow +71,2% YoY
• ▍Net margin -564.0%

Revenue $2.7M, −89,2% YoY; Operating income +69,7% YoY.

• ▍Revenue $2.7M, −89,2% YoY
• ▍Operating income +69,7% YoY
• ▍Net income +114,1% YoY
• ▍Free cash flow +66,2% YoY
• ▍Net margin 169.4%

Revenue $3.1M; Operating income -$91.7M.

• ▍Revenue $3.1M
• ▍Operating income -$91.7M
• ▍Net margin 573.6%

Revenue $123.0k; Operating income -$47.7M.

• ▍Revenue $123.0k
• ▍Operating income -$47.7M
• ▍Net margin -13889.4%

Revenue $998.0k; Operating income -$46.4M.

• ▍Revenue $998.0k
• ▍Operating income -$46.4M
• ▍Net margin -1557.5%

Revenue $25.4M; Operating income -$49.2M.

• ▍Revenue $25.4M
• ▍Operating income -$49.2M
• ▍Net margin -129.8%

Revenue $6.4M, −78,3% YoY; Operating income +65,1% YoY.

• ▍Revenue $6.4M, −78,3% YoY
• ▍Operating income +65,1% YoY
• ▍Net income +485,6% YoY
• ▍Free cash flow +62,2% YoY
• ▍Net margin 2848.6%

Revenue $29.6M, −36,7% YoY; Operating income +53,4% YoY.

• ▍Revenue $29.6M, −36,7% YoY
• ▍Operating income +53,4% YoY
• ▍Net income +83,3% YoY
• ▍Free cash flow +52,2% YoY
• ▍Net margin -160.6%

Revenue $46.8M, −66,7% YoY; Operating income −7,2% YoY.

• ▍Revenue $46.8M, −66,7% YoY
• ▍Operating income −7,2% YoY
• ▍Net income +3,2% YoY
• ▍Free cash flow +1,6% YoY
• ▍Net margin -607.3%

Revenue $140.7M, −40,2% YoY; Operating income −4,3% YoY.

• ▍Revenue $140.7M, −40,2% YoY
• ▍Operating income −4,3% YoY
• ▍Net income −1,2% YoY
• ▍Free cash flow −5,5% YoY
• ▍Net margin -208.7%